Risk of Liver-Associated Morbidity and Mortality in a Cohort of HIV and HBV Coinfected Han Chinese.

R. Yang,X. Gui,Y. Xiong,S. Gao,Y. Zhang,L. Deng,K. Liang,Y. Yan,Y. Rong

DOI: https://doi.org/10.1007/s15010-011-0145-1

2011-01-01

Infection

Abstract:To investigate the incidence and risk factors of liver-associated morbidity and mortality in Han Chinese patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection.

What problem does this paper attempt to address?

End-stage Liver Disease: Prevalence, Risk Factors and Clinical Characteristics in a Cohort of HIV-HCV Coinfected Han Chinese.

Liping Deng,Xien Gui,Yong Xiong,Shicheng Gao,Rongrong Yang,Yuping Rong,Jinzhi Hu,Yajun Yan

DOI: https://doi.org/10.1016/j.clinre.2012.02.007

IF: 3.189

2012-01-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:Introduction: Since the advent of combined antiretroviral therapy (cART), liver-related mortality has become the leading cause of non-AIDS-related deaths in human immunodeficiency virus (HIV) infected patients in Western countries.Objective: To investigate the incidence, mortality and risk factors of end-stage liver disease (ESLD) in HIV and hepatitis C virus (HCV) coinfected former plasma donors (FPDs) and blood recipients (BRs).Method: A retrospective study was conducted.Results: Of 321 HIV-HCV coinfected patients, 42 (13.1%) developed ESLD and 40 (12.5%) died. Factors that were independently associated with ESLD included older age at baseline (Odds ratios [OR]: 2.444, P = 0.035), alanine aminotransferase (ALT) greater or equal to 2 (the upper limit of normal [ULN]) at the end of follow-up (OR: 16.460, P = 0.000), hepatitis B virus (HBV) (OR: 2.525, P = 0.043), CDC stage C (OR: 5.806, P = 0.001), duration of cART greater than 5 years (OR: 3.256, P = 0.010), and CD4 count greater or equal to 200 cells/mm(3) at the end of follow-up (OR: 0.383, P = 0.016). The probability of developing ESLD in HIV-HCV coinfected BRs was significantly higher than in FPDs (P = 0.008). Mortality was also significantly higher in HIV-HCV coinfected patients with ESLD than in those without ESLD (P = 0.000).Conclusion: In the cART era, ESLD was common among HIV-HCV coinfected Han Chinese patients and was responsible for reducing patient survival time. (c) 2012 Elsevier Masson SAS. All rights reserved.
Impact of Hepatitis B Virus Infection on HIV Response to Antiretroviral Therapy in a Chinese Antiretroviral Therapy Center.

Rongrong Yang,Xien Gui,Yong Xiong,Shi-cheng Gao,Yajun Yan

DOI: https://doi.org/10.1016/j.ijid.2014.07.018

IF: 12.073

2014-01-01

International Journal of Infectious Diseases

Abstract:BACKGROUND:Co-infection with hepatitis B virus (HBV) and HIV is common in China; however, the impact of HBV on long-term antiretroviral therapy (ART) outcomes has not been fully characterized.METHODS:Patients were classified as being HIV mono-infected (hepatitis B surface antigen (HBsAg)-negative) or HIV/HBV co-infected (HBsAg-positive). The effects of HBV on HIV virological response, changes in CD4 cell counts, hepatotoxicity, and mortality among Chinese patients receiving ART were evaluated.RESULTS:The HIV/HBV co-infection rate in our cohort was 9.9% (354/3562). Five hundred and fifty HIV mono-infected and 78 HIV/HBV co-infected individuals fulfilled the inclusion criteria. HIV/HBV co-infected individuals were less likely to achieve HIV-RNA suppression and a CD4 increase than HIV mono-infected individuals at 48 months post-ART. Greater hepatotoxicity and a more rapid occurrence of death were observed in HIV/HBV co-infected subjects. HBV-related mortality accounted for 84.2% (16/19) of the total deaths in HIV/HBV co-infected subjects.CONCLUSIONS:HBV co-infection can affect late immunological and virological responses to ART and increase the risk of hepatotoxicity. Mortality due to liver disease was high among HIV/HBV co-infected individuals in this study, despite HBV-active ART. As long as HIV/HBV co-infected persons need anti-HBV therapy, they should be recommended ART that includes agents with activity against both HIV and HBV, regardless of the CD4 cell count level.
Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis.

Jia-Jia Chen,Cheng-Bo Yu,Wei-Bo Du,Lan-Juan Li

DOI: https://doi.org/10.1016/S1499-3872(11)60020-9

IF: 3.355

2011-01-01

Hepatobiliary & Pancreatic Diseases International

Abstract:Hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV) share similar routes of transmission by sexual intercourse or drug use by parenteral injection, so coinfection is common. This study aimed to determine the prevalence of coinfection with either HCV or HBV in patients infected with HIV.A meta-analysis was performed to quantify HBV coinfection with HCV in HIV patients. Published studies in the English and Chinese language medical literature involving cohorts of HIV patients concomitantly infected with HBV and/or HCV were collected from the PubMed database, ISI Web of Science, the Cochrane library clinical trials registry, CNKI (China National Knowledge Infrastructure) and Google Scholar, for relevant articles before November 2009. The search was conducted with the following key words: hepatitis C, HCV, hepatitis B, HBV, human immunodeficiency virus, HIV, and coinfection. Data were extracted from relevant studies by two investigators. RevMan 5.0 software was used to perform the meta-analysis.We identified 22 studies involving 17 664 patients. Substantial differences in the HCV rate compared to the HBV rate in HIV patients were found in the overall analysis [odds ratio (OR)=3.00; 95% confidence interval (CI) 1.90-4.73]. A subgroup analysis showed similar results in a European group, but not in Asian or African groups. However, a meta-analysis between HIV+HBV+HCV+ and HIV+HBV+HCV- patients showed no significant difference (OR=0.91; 95% CI 0.57-1.45). Although subgroup analysis still lacked essential differences, different regions seemed to have different patterns.HCV-HIV coinfection is more frequent than HBV-HIV coinfection overall. However, HCV infection does not affect the prevalence of HBV infection in HIV-positive patients.
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.

Shu Su,Christopher K Fairley,Joe Sasadeusz,Jianmei He,Xiuqing Wei,Huan Zeng,Jun Jing,Limin Mao,Xi Chen,Lei Zhang

DOI: https://doi.org/10.1002/jmv.24988

IF: 20.693

2018-01-01

Journal of Medical Virology

Abstract:Co-infection with hepatitis B (HBV) and C (HCV) is common among people living with HIV (PLHIV). This study investigates the impacts of hepatitis co-infection on antiretroviral therapy (ART) outcomes and hepatotoxicity in PLHIV. The cohort study included 1984 PLHIV. Hepatotoxicity was defined by elevated alanine aminotransferase (ALT) levels. ART outcomes were measured by CD4 cell counts, viral load, and mortality rate in patients. Among 1984 PLHIV, 184 (9.3%) were co-infected with HBV and 198 (10.0%) with HCV and 54 (2.7%) were co-infected with HBV and HCV. Of these patients, 156 (7.9%) had ALT elevationgrade 1 at baseline. During the course of ART, the mortality rate and its adjusted hazard ratio (AHR) in PLHIV who were co-infected with HCV (2.6/100person-years [py], AHR=2.3, 95%CI 1.1-4.7) was higher than for patients with mono-infected HIV, as it was for those with an elevated ALT (4.4/100 py, AHR=3.8, [1.7-8.2]) at baseline compared to those with normal ALT. After 6-12 months of ART, the incidence of hepatotoxicity among all the patients was 3.7/100 py. The risk of hepatotoxicity was higher in HCV co-infected (18.6/100py, adjusted odds ratio [AOR]=12.4, [8.1-18.2]) than HIV mono-infected patients, and for all regimens (nevirapine: 30.0/100py, 34.2, 7.3-47.9; zidovudine/stavudine: 24.7/100py, 22.1, 7.1-25.5; efavirenz: 14.5/100py, 9.4, 3.5-19.2; lopinavir/ritonavir: 40.1/100py, 52.2, 9.5-88.2) except tenofovir (4.3/100py, 4.9, 0.8-9.5). Patients with HBV/HCV co-infected had high hepatotoxicity (10.0/100py, 6.3, 1.2-23.3) over the same period. Patients with HCV co-infection and HBV/HCV co-infection demonstrated higher hepatotoxicity rate compared with HIV mono-infected patients in China.
Health-Related Quality Of Life And Its Influencing Factors In Patients With Hepatitis B: A Cross-Sectional Assessment In Southeastern China

Ping Chen,Fen Zhang,Yiqun Shen,Yubo Cai,Chaolei Jin,Yan Li,Mingmin Tu,Weizhen Zhang,Yu Wang,Shi-Feng Zhang,Jiangyun Wang,Lanjuan Li

DOI: https://doi.org/10.1155/2021/9937591

2021-01-01

Canadian Journal of Gastroenterology and Hepatology

Abstract:Health-related quality of life (HRQoL) is an important aspect in the management of patients with hepatitis B (HB), which remains a serious health problem in China. There have been relatively few HRQoL studies involving Chinese patients with HB. The aim of this study was to analyze HRQoL in patients diagnosed with HB living in Zhejiang Province, China. A cross-sectional sample of 98 patients with chronic HB (CHB), 56 patients with advanced HB that have developed cirrhosis, and 48 healthy controls (HCs), all from Zhejiang Province, was used in this study. HRQoL was assessed using Short-Form 36 (SF-36) version 2, European quality of life questionnaire-5 dimensions (EQ-5D), and chronic liver disease questionnaire (CLDQ). Intergroup score differences were detected with U tests. Factors with a significant effect on HRQoL were identified with Spearman correlational analyses. Patients with HB (both groups) had lower SF-36 scores than HCs (p<0.01), with the exception of general health subscores. Patients with HB cirrhosis had the lowest scores in the EQ-5D visual analog scale (VAS) component. Furthermore, patients with HB cirrhosis had lower (p<0.01) CLDQ scores than patients with CHB. In our HB patient cohort, disease stage and income level were the factors most associated with HRQoL variables; age, education level, and marital status were, each, also significantly associated with some HRQoL variables in patients with HB in our study (p<0.05 or p<0.01). HRQoL is diminished in patients with HB in southeastern China. Disease stage and income emerged as key determinants of HRQoL scores. Augmenting social and medical supports for patients with HB, especially those with a socioeconomic status and an advanced disease stage, may help to enhance HRQoL.
Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicentre Descriptive Study

Jian Wu,Jiong Yu,Xiaowei Shi,Wei Li,Shu Song,Liangping Zhao,Xinguo Zhao,Jun Liu,Dawei Wang,Chengyuan Liu,Biao Huang,Yiling Meng,Bin Jiang,Yijun Deng,Hongcui Cao,Lanjuan Li

DOI: https://doi.org/10.1111/jvh.13404

2020-01-01

Journal of Viral Hepatitis

Abstract:The interaction between existing chronic liver diseases caused by hepatitis B virus (HBV) infection and COVID‐19 has not been studied. We analysed 70 COVID‐19 cases combined with HBV infection (CHI) to determine the epidemiological, clinical characteristics, treatment and outcome. We investigated clinical presentation, imaging and laboratory parameters of COVID‐19 patients of seven hospitals from Jan 20 to March 20, 2020. Multivariate analysis was used to analyse risk factors for progression of patients with COVID‐19 combined with HBV infection. Compared with COVID‐19 without HBV infection (WHI) group, patients with dual infection had a higher proportion of severe/critically ill disease (32.86% vs. 15.27%, P = .000), higher levels of alanine aminotransferase (ALT), aspartate transaminase (AST) and activated partial thromboplastin (APTT) [50(28‐69)vs 21(14‐30), P = .000; 40(25‐54) vs 23(18‐30), P = .000; 34.0(27.2‐38.7) vs 37.2(31.1‐41.4), P = .031]. The utilization rates of Arbidol and immunoglobulin were significantly higher than those in the co‐infected group [48.57% vs. 35.64%, P < .05; 21.43% vs. 8.18%, P < .001], while the utilization rate of chloroquine phosphate was lower (1.43% vs 14.00%, P < .05) in the co‐infected patients group. Age and c‐reactive protein (CRP) level were independent risk factors for recovery of patients with COVID‐19 combined with HBV infection. The original characteristics of COVID‐19 cases combined with HBV infection were higher rate of liver injury, coagulation disorders, severe/critical tendency and increased susceptibility. The elderly and patients with higher level of CRP were more likely to experience a severe outcome of COVID‐19.
Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis

Songxia Yu,Chengbo Yu,Jian Li,Shiming Liu,Haowen Wang,Min Deng

DOI: https://doi.org/10.1186/s12985-020-01404-z

IF: 5.916

2020-08-24

Virology Journal

Abstract:Abstract Background There has been little published data on estimates of HBV and/or HCV coinfection in HIV-positive patients in China or an understanding of how this coinfection varies with different factors. Therefore, this study aimed to determine, through a systematic review and meta-analysis, the prevalence of HBV and/or HCV in HIV-positive patients in China and explore variations in prevalence. Methods The Medicine, Web of Science, Chinese Web of Knowledge, and Wanfang databases were searched using a search strategy combining key words and related disease-specific subject terms to identify relevant cohort or cross-sectional studies published up to April 2019. Included articles were assessed for quality. Pooled prevalence and 95% confidence intervals (CIs) were calculated according to study region and other specific characteristics. Results Our searches identified 7843 records, but only 66 studies were included in our meta-analysis. The pooled HBsAg prevalence in HIV-positive patients was 13.7% (95% CI 12.3–15.3%), with variations found in terms of age and geographic region. The meta-HCV prevalence was 24.7% (95% CI 19.3–30.5%), which varied over the study period and age. The pooled HBV-HCV coinfection prevalence was 3.5% (95% CI 2.4–4.8%), with variations found in terms of age and geographic region. Conclusion Given the high burden of HBV and HCV coinfections in HIV-positive patients, the incorporation of comprehensive screening, treatment, prevention, and vaccination programs into general HIV management in China is imperative.

virology
Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Jingya Jia,Qiuying Zhu,Luojia Deng,Guanghua Lan,Andrew Johnson,Huanhuan Chen,Zhiyong Shen,Jianjun Li,Hui Xing,Yuhua Ruan,Jing Li,Hui Lu,Sten H. Vermund,Jinhui Zhu,Han-Zhu Qian

DOI: https://doi.org/10.1186/s40249-021-00921-5

2022-01-06

Infectious Diseases of Poverty

Abstract:Abstract Background Antiretroviral therapy (ART) has reduced mortality among people living with HIV (PLWH) in China, but co-infections of hepatitis B virus (HBV) and hepatitis C virus (HCV) may individually or jointly reduce the effect of ART. This study aimed to evaluate the impacts of HBV/HCV coinfections on treatment drop-out and mortality among PLWH on ART. Methods A retrospective cohort study analysis of 58 239 people living with HIV (PLWH) who initiated antiretroviral therapy (ART) during 2010–2018 was conducted in Guangxi Province, China. Data were from the observational database of the National Free Antiretroviral Treatment Program. Cox proportional hazard models were fitted to evaluate the effects of baseline infection of HBV or HCV or both on death and treatment attrition among PLWH. Results Our study showed high prevalence of HBV (11.5%), HCV (6.6%) and HBV-HCV (1.5%) co-infections. The overall mortality rate and treatment attrition rate was 2.95 [95% confidence interval ( CI ) 2.88–3.02] and 5.92 (95% CI 5.82–6.01) per 100 person-years, respectively. Compared with HIV-only patients, HBV-co-infected patients had 42% higher mortality [adjusted hazard ratio (a HR ) = 1.42; 95% CI 1.32–1.54], HCV-co-infected patients had 65% higher mortality (a HR = 1.65; 95% CI 1.47–1.86), and patients with both HCV and HBV co-infections had 123% higher mortality (a HR = 2.23; 95% CI 1.87–2.66). Conclusions HBV and HCV coinfection may have an additive effect on increasing the risk of all-cause death among PLWH who are on ART. It is suggested that there is need for primary prevention and access to effective hepatitis treatment for PLWH. Graphical Abstract

infectious diseases,tropical medicine,parasitology
Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in China

Xiaoyang Li,Yu Zheng,Hongming Zhu,Xiaojing Lin,Yunxiang Zhang,Yubing Zhao,Jiong Hu,Junmin Li

DOI: https://doi.org/10.1159/000468973

2017-01-01

Acta Haematologica

Abstract:The hepatitis B virus (HBV) is a major global issue, because an increased risk of hepatocellular carcinoma among patients infected with HBV is well established. Recently, it has been suggested that HBV is associated with other human cancers. However, the association between HBV and the risk of onset of hematological malignancies remains controversial. The aim of this large-scale retrospective cohort study was to evaluate the association between HBV infection and hematological malignancies. A retrospective analysis of 86,115 newly admitted patients at Shanghai Ruijin Hospital was performed. A cohort of patients previously exposed to HBV (n = 1,874) and a cohort of individuals without a positive test for anti-hepatitis B core antigen (anti-HBc; n = 45,118) were compared to assess the risk of hematological malignancies. Anti-HBc was positive in 61.2% cases and 54.3% controls (p = 0.0001). The risk of B cell non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and multiple myeloma was higher in the HBV-infected cohort than in the non-HBV-infected cohort. In conclusion, patients infected with HBV have a substantially increased risk of hematological malignancies.
Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus.

Pingzheng Mo,Qi Zhu,Caroline Teter,Rongrong Yang,Liping Deng,Yajun Yan,Jun Chen,Jie Zeng,Xi-en Gui

DOI: https://doi.org/10.1016/j.ijid.2014.06.020

IF: 12.073

2014-01-01

International Journal of Infectious Diseases

Abstract:•TB patients have a higher infection rate of HIV.•HIV-positive TB patients have a higher rate of HCV infection.•HIV, HBV and HCV are risk factors for the development of abnormal LFTs.•Hepatitis viral load is an important predictor for the development of abnormal LFTs.•HIV, HBV and HCV are risk factors for mortality during anti-TB treatment.
Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus–Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys

Lin Liu,Lin Wang,Hua Zhang,Weidong Ou,Dan Li,Yi Feng,Hui Zhuang,Yiming Shao

DOI: https://doi.org/10.1093/cid/ciab058

IF: 20.999

2021-01-27

Clinical Infectious Diseases

Abstract:Abstract Background The transmission of human immunodeficiency virus (HIV) and hepatitis B virus (HBV)/hepatitis C virus (HCV) is similar in modes/routes and related risk factors. Understanding the long-term changing epidemiology of HIV, HBV, and HCV coinfection is important for evaluation of existing disease control policy and healthcare planning. We describe HBV and HCV coinfection based on the latest 2 nationwide molecular epidemiologic surveys of HIV infection in mainland China in 2007 and 2015. Methods Seroprevalence of HBV and HCV infections was determined in antiretroviral treatment (ART)–naive people living with HIV-1 (PLWH) from 2 nationwide surveys conducted in 2007 and 2015 from 31 provinces, municipalities, and autonomous regions in mainland China. Demographic characteristics, route of HIV transmission, and CD4+ cell count were captured in the national database. Logistic regression was used to study the association between coinfection status and possible relevant risk factors. Results A total of 6611 (n = 1571 in 2007; n = 5040 in 2015) ART-naive PLWH met the eligibility criteria. The prevalence of HBV and HCV coinfection in PLWH decreased from 61.1% in 2007 to 18.0% in 2015. Significant coinfection proportion reduction was found for HCV (from 53.7% to 4.9%), and a moderate decrease for HBV (17.8% to 13.9%). There was an increase of HBV/HIV coinfections among 12 provinces, municipalities, and autonomous regions, associated with domestic migration (adjusted odds ratio, 6.34 [95% confidence interval, 1.82–22.09]). Conclusions A significant decrease of HBV and HCV coinfection in PLWH was observed. Due to limited health resources and high transmission efficiency, concerted efforts should be made to further control viral hepatitis epidemics in HIV-positive populations.

immunology,infectious diseases,microbiology
[Prevalence and Related Factors of HIV/HBV Coinfection among HIV/AIDS Patients].

Dan Feng,Yao Tian,Yanpeng Cheng,Minghu Pan,Chunxia Li,Wang Jun,Yongliang Feng,Jing Shi,Honglang Huang,Hongzhou Lu,Guanghua Lan,Suping Wang,Yawei Zhang

DOI: https://doi.org/10.3760/cma.j.issn.0254-6450.2017.12.008

2017-01-01

Abstract:Objective: To reveal the prevalence and the related factors of hepatitis B (HepB) virus infection among HIV/AIDS patients. Methods: We conducted a cross-sectional study in two HIV clinics, affiliated to local Centers of Disease Control and Prevention in Guangxi Zhuang Autonomous Regional. A face-to-face interview, with questionnaire was conducted to collect information on socio-demographic characteristics, drug use, and sexual behavior. Blood samples were used to test HBsAg. χ(2) test or Fisher's exact test and unconditional logistic regression models were used to identify the influencing factors. Results: The prevalence of HBV and HIV co-infection was 13.85% (113/816). Results from multivariate logistic regression analyses showed that age (25-45), family history of HBV and history of HepB vaccination were independent influencing factors for HBV and HIV coinfection, with OR (95%CI) as 1.738 (1.031-2.931), 2.898 (1.678-5.005) and 1.744 (1.052-2.892), respectively. Conclusion: The prevalence of HBV among HIV/AIDS patients was significantly higher than that in general population. HIV/AIDS patients aged between 25 and 45 and with family history of HBV were more likely to be infected with HBV, while HepB vaccination was associated with the reduction of HIV/HBV coinfection. Specific comprehensive prevention and treatment programs on HIV/AIDS patients need to be set up.
HBV and HCV Co-Infection in Chinese Newly Diagnosed HIV+ Subjects in 2015 and 2023: A Cross-Sectional Study

Fangyuan Li,Yi Feng,Xiu Liu,Jingjing Hao,Dong Wang,Hongping Hu,Chang Song,Jing Hu,Quanbi Zhao,Hua Liang,Lingjie Liao,Yuhua Ruan,Hui Xing

DOI: https://doi.org/10.3390/pathogens13050367

IF: 3.7

2024-04-29

Pathogens

Abstract:With shared routes of transmission, HBV and HCV co-infection are estimated to occur more in subjects with HIV. This study aimed to characterize and describe the prevalence of HBV and HCV co-infections in a cohort of newly diagnosed HIV+ subjects living in China. We conducted a cross-sectional study among newly diagnosed HIV+ subjects aged 18–100 who participated in surveys on the national HIV molecular epidemiology in 2015 and 2023. (The epidemiological table survey is located in the national database alongside serologic testing). The chi-square test was used to identify changes in infections between the studying populations in 2015 and 2023, and conditional logistic regression models were fit to identify risk factors for each co-infection. Among the 11,024 newly diagnosed HIV+ subjects who were surveyed (n = 4501 in 2015; n = 6523 in 2023), the prevalence of HBV, HCV, and HBV/HCV in 2023 was lower than that in 2015, respectively. No decrease was observed in HCV co-infection in men who had sex with men (MSM) in North China, Northeast China, and East China. Increasing recognition among those at high risk of heterosexual transmission and those with low educational backgrounds is paramount to the prevention and control of HIV/HBV/HCV infections.

microbiology
Logistic Regression Analysis for Risk Factors Related to End-Stage Liver Disease among HIV/HBV Co-Infection Patients

YANG Rong-rong,GUI Xi-en,GAO Shi-cheng,XIONG Yong,DENG Li-ping,RONG Yu-ping

DOI: https://doi.org/10.3760/cma.j.issn.1671-7368.2011.09.010

2011-01-01

Abstract:Objective To understand major risk factors associated with end-stage liver disease (ESLD) among patients with human immunedeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.Methods Patients with HIV/HBV co-infection were followed-up and factors related to ESLD were analyzed using logistic regression model to estimate odds ratios (ORs) for them. Results A total of 255 patients with HIV/HBV co-infection were investigated, with an incidence of ESLD of 19. 2% ( 49/255 ). Major risk factors associated with ESLD among patients with HIV/HBV co-infection included count of CD4 below 200 cells/μl at baseline, HIV RNA load decreasing to the lower limit of its detection level within six months after antiretroviral treatment (ART), abnormal of serum activities of transaminase (ALT or AST), longer persistently positive of HIV RNA and HBV DNA, and use of lamivudine-based ART, with OR of 6. 503,14. 456, 0. 049, 1. 814, 1. 536 and 0. 012, respectively. Conclusions Lower CD4 count, abnormal serum transaminases, persistent replication of HIV and HBV all are closely related to ESLD in patients with HIV/HBV co-infection. Therefore, lamivudine-based ART should be of choice for patients with HIV/HBV coinfection to decrease incidence of ESLD.
Liver Injury in Patients with Hepatitis C Virus/human Immunodeficiency Virus Coinfection in Dehong Prefecture, Yunnan Province

Yang Yuecheng,Shen Qinfeng,Tang Renhai,Yao Shitang,Duan Song,He Na

DOI: https://doi.org/10.3760/cma.j.issn.1000-6680.2016.04.004

2016-01-01

Abstract:Objective To evaluate liver injury in patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection in Dehong Prefecture,Yunnan Province.Methods A total of 4 784 HIV-infected patients were enrolled in this study.Baseline aspartate aminotransferase (AST),alanine aminotransferase (ALT) and AST-to-platelet ratio index (APRI) before HIV treatment were collected to analyze the relationship between HCV infection and liver injury.Data were analyzed by x2 test and nonparametric rank sum test when appropriate.Risk factors for liver injury were analyzed by multivariate Logistic regression.Results Totally 4 784 patients were included,of which 30.2％ (1 447/ 4 784) were anti-HCV positive,41.7％ (1 996/4 784) had liver dysfunction and 13.3％ (636/4 784) had liver cirrhosis.Prevalence of liver dysfunction (61.1％,821/1 343) and cirrhosis (24.1 ％,323/1 343) were significantly higher among anti-HCV-positive patients than anti-HCV-negative patients (31.5％,974/3 092,X2=341.223,P＜0.01;7.5％,231/3 092,X2=235.457,P＜0.01,respectively).Multivariate Logistic regression showed that anti-HCV-positive patients suffered significantly higher risk of liver dysfunction (OR=1.99,95％ CI:1.66-2.37) and liver cirrhosis (OR=2.41,95％CI:1.90-3.04).Conclusion Patients with HCV/HIV in Dehong Prefecture coinfection had a higher risk for liver injury.
Risk factors of death in HIV/HCV co-infected patients with combined antiretroviral therapy

Li-PING DENG,Xi-en GUI,Yong XIONG,Shi-cheng GAO,Yu-ping RONG,Rong-rong YANG,Jin-zhi HU

DOI: https://doi.org/10.3760/cma.j.issn.1674-2397.2012.03.007

2012-01-01

Abstract:Objective To analyze the incidence,mortality and risk factors of death in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) co-infected patients with combined antiretroviral therapy (cART).Methods A total of 427 HIV/HCV co-infected patients admitted to Zhongnan Hospital of Wuhan University or local disease prevention and control canters from January 2003 to December 2010 were enrolled in the study.The demographic and clinical data of patients were retrospectively studied.Cox progressive regression model was used for data analysis,and Kaplan-Meier method was used to evaluate the effect of end-stage liver diseases on the death.Results of 427 HIV/HCV co-infected patients,53 ( 12.4％ ) died during the follow-up,in which 28 (52.8％) died of liver-related diseases.Male gender ( RR =2.63,P =0.05 ),infection via blood transfusion ( RR =2.15,P =0.04),baseline CD4 + T cells ＜50 cells/μL ( RR =2.83,P =0.02),HIV RNA≥ 104copies/mL at the end of follow-up (RR =2.79,P =0.00 ) and complicated with end-stage liver disease ( RR =7.79,P =0.00) were significantly related to the death.Duration of cART ＞ 5 years is a protective factor for the death ( RR =0.03,P =0.00).Themortality of patients complicated with end-stage liver diseases was 52.7％ ( 29/55 ).Conclusion Liver disease-related death has become the leading cause of death in HIV/HCV co-infected patients,and patients with end-stage liver diseases are of high risk of death.
Replication Inhibition Of Hepatitis B Virus And Hepatitis C Virus In Co-Infected Patients In Chinese Population

Ge Yu,Xiumei Chi,Ruihong Wu,Xiaomei Wang,Xiuzhu Gao,Fei Kong,Xiangwei Feng,Yuanda Gao,Xinxing Huang,Jinglan Jin,Yue Qi,Zhengkun Tu,Bing Sun,Jin Zhong,Yu Pan,Junqi Niu

DOI: https://doi.org/10.1371/journal.pone.0139015

IF: 3.7

2015-01-01

PLoS ONE

Abstract:BackgroundHepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections contributes to a substantial proportion of liver disease worldwide. The aim of this study was to assess the clinical and virological features of HBV-HCV co-infection.MethodsDemographic data were collected for 3238 high-risk people from an HCV-endemic region in China. Laboratory tests included HCV antibody and HBV serological markers, liver function tests, and routine blood analysis. Anti-HCV positive samples were analyzed for HCV RNA levels and subgenotypes. HBsAg-positive samples were tested for HBV DNA.ResultsA total of 1468 patients had chronic HCV and/or HBV infections. Among them, 1200 individuals were classified as HCV mono-infected, 161 were classified as HBV mono-infected, and 107 were classified as co-infected. The HBV-HCV co-infected patients not only had a lower HBV DNA positive rate compared to HBV mono-infected patients (84.1% versus 94.4%, respectively; P<0.001). The median HCV RNA levels in HBV-HCV co-infected patients were significantly lower than those in the HCV mono-infected patients (1.18[Interquartile range (IQR) 0-5.57] versus 5.87[IQR, 3.54-6.71] Log(10) IU/mL, respectively; P<0.001). Furthermore, co-infected patients were less likely to have detectable HCV RNA levels than HCV mono-infected patients (23.4% versus 56.5%, respectively; P<0.001). Those HBV-HCV co-infected patients had significantly lower median HBV DNA levels than those mono-infected with HBV (1.97[IQR, 1.3-3.43] versus 3.06[IQR, 2-4.28] Log(10) IU/mL, respectively; P<0.001). The HBV-HCV co-infection group had higher ALT, AST, ALP, GGT, APRI and FIB-4 levels, but lower ALB and total platelet compared to the HBV mono-infection group, and similar to that of the HCV mono-infected group.ConclusionThese results suggest that co-infection with HCV and HBV inhibits the replication of both viruses. The serologic results of HBV-HCV co-infection in patients suggests more liver injury compared to HBV mono-infected patients, but is similar to HCV mono-infection.
Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV - Guangxi Zhuang Autonomous Region, China, 2003-2022

He Jiang,Qiuying Zhu,Jinghua Huang,Xiuling Wu,Bo Li,Xuanhua Liu,Qin Meng,Shuai Tang,Guanghua Lan

DOI: https://doi.org/10.46234/ccdcw2023.183

2023-01-01

China CDC Weekly

Abstract:What is already known about this topic? The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research. What is added by this report? According to the propensity score-matched cohort, individuals with HIV/HCV co-infection exhibit an elevated risk of all-cause mortality [adjusted hazard ratio: 2.048, 95% confidence interval (CI): 1.526-2.749] and attrition (adjusted incidence rate ratio: 1.659, 95% CI: 1.4.8-1.961) compared to their counterparts who are mono-infected with HIV. What are the implications for public health practice? The pressing need for tailored testing and follow-up protocols for individuals co-infected with HIV/HCV cannot be overstated.
The Variation of the Infection with Hepatitis B, C and E Viruses in HIV-1 Positive Patients in China

Lin Liu,Hua Zhang,Dan Li,Weidong Ou,Yanyan Shi,Hui Zhuang,Yiming Shao

DOI: https://doi.org/10.2139/ssrn.3493224

2019-01-01

Abstract:Background: HIV-1 and viral hepatitis have similar transmission moods and social factors related to their infections. This research aims to study the prevalence of co-infection of HIV-1 and hepatitis B virus (HBV) /hepatitis C virus (HCV)/hepatitis E virus (HEV).Methods: The prevalence of HBV, HCV and HEV infections were measured in two Chinese national HIV-1 molecular surveys at 2007 and 2015. The individuals were recruited from 31 cities and provinces. Demographic characteristics, route of HIV transmission and CD4 cells count, were captured in the national HIV epidemiology database. The infection of HIV, HBV, HCV and HEV was detected using plasma specimens. Logistic regression was used to study the association between co-infections status and possibly relevant factors.Finding: The viral hepatitis co-infections in HIV-1 infected populations were decreased from 75.6% in 2007 to 44.1% in 2015. Significant co-infection reductions were found for HCV (from 51.1% to 4.9%) and HBV (17.8% to 13.9%) and HEV co-infections (41.7% to 32.8%). There is an increase of 4.4% HBV co-infections among MSM between the two surveys. And the increase might be associated with migrations from high to low HBV epidemic regions [AOR=6.34, 95% CI: (1.82, 22.1)).Interpretation: This study showed that there were significant decreases in the co-infections of HBV, HCV and HEV in HIV infected populations. Due to the limited health resources and higher transmission efficiency of the viral hepatitis than HIV-1, concerted efforts should be made to further control the viral hepatitis epidemics in HIV affected populations.Funding Statement: This study was supported by National Natural Science Foundation of China (Grants 31600734).Declaration of Interests: All the authors declare that they have no conflict of interest.Ethics Approval Statement: This study was approved by the institutional review board at the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. In the sample collection, all participants provided informed written consent.
Hepatitis B Virus Infection in Chinese Patients with Hepatitis C Virus Infection: Prevalence, Clinical Characteristics, Viral Interactions and Host Genotypes: a Nationwide Cross-Sectional Study

Li-Bo Yan,Hui-Ying Rao,Yuan-Ji Ma,Lang Bai,En-Qiang Chen,Ling-Yao Du,Rui-Feng Yang,Lai Wei,Hong Tang

DOI: https://doi.org/10.1136/bmjopen-2016-012016

IF: 3.006

2016-01-01

BMJ Open

Abstract:Objectives Little is known about hepatitis B virus (HBV) infection in patients with hepatitis C virus (HCV) infection in China. This study aimed to evaluate the prevalence, clinical characteristics, viral interactions and host genotypes of HBV/HCV dual infection compared with HCV monoinfection. Study design A cross-sectional study. Setting China. Participants and methods 997 patients with HCV from 28 university-affiliated hospitals in China were enrolled in this research. Patients were divided into two subgroups. Results The prevalence of HBV infection in patients with HCV was 4.11% (41/997). The age-specific prevalence of HBsAg was 0.70%, 3.97% and 5.85% in groups aged 18–30, 30–50 and >50 years old (p=0.057), respectively. Patients with HBV/HCV dual infection and patients with HCV monoinfection had similar HCV viral loads (5.80±0.89 vs 5.83±1.00 log10 IU/mL, p=0.904). The dominant HCV genotype was 1b in both groups (53.65% vs 56.90%, p=0.493). The protective C allele in IL-28B (rs12979860) was also the dominant allele type in both patient groups (85.36% vs 83.99%, p=0.814). Patients with HBV/HCV dual infection had a higher ratio of liver cirrhosis and hepatic decompensation than patients with HCV monoinfection (39.02% vs 17.69%, p=0.001; 31.70% vs 12.13%, p=0.001). Conclusions The HBV burden was moderate in HCV-infected patients in China. Liver cirrhosis was more common in patients with HBV/HCV dual infection, suggesting the need for closer monitoring of dual-infected individuals. Trial registration number NCT01293279; Post-results.

Risk of Liver-Associated Morbidity and Mortality in a Cohort of HIV and HBV Coinfected Han Chinese.

End-stage Liver Disease: Prevalence, Risk Factors and Clinical Characteristics in a Cohort of HIV-HCV Coinfected Han Chinese.

Impact of Hepatitis B Virus Infection on HIV Response to Antiretroviral Therapy in a Chinese Antiretroviral Therapy Center.

Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis.

HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.

Health-Related Quality Of Life And Its Influencing Factors In Patients With Hepatitis B: A Cross-Sectional Assessment In Southeastern China

Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicentre Descriptive Study

Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis

Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in China

Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus.

Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus–Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys

[Prevalence and Related Factors of HIV/HBV Coinfection among HIV/AIDS Patients].

HBV and HCV Co-Infection in Chinese Newly Diagnosed HIV+ Subjects in 2015 and 2023: A Cross-Sectional Study

Logistic Regression Analysis for Risk Factors Related to End-Stage Liver Disease among HIV/HBV Co-Infection Patients

Liver Injury in Patients with Hepatitis C Virus/human Immunodeficiency Virus Coinfection in Dehong Prefecture, Yunnan Province

Risk factors of death in HIV/HCV co-infected patients with combined antiretroviral therapy

Replication Inhibition Of Hepatitis B Virus And Hepatitis C Virus In Co-Infected Patients In Chinese Population

Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV - Guangxi Zhuang Autonomous Region, China, 2003-2022

The Variation of the Infection with Hepatitis B, C and E Viruses in HIV-1 Positive Patients in China

Hepatitis B Virus Infection in Chinese Patients with Hepatitis C Virus Infection: Prevalence, Clinical Characteristics, Viral Interactions and Host Genotypes: a Nationwide Cross-Sectional Study